SCHEMBL2106459

SCHEMBL2106459

C[C@@H]1C[C@]2(NC(=O)NC2=O)c2cc(F)ccc2O1

nearest known ligand 0.69

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 13/20 0.69
AKR1B10 O60218 2/20 0.69
AKR1A1 P14550 2/20 0.69
MAPT P10636 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1201112 1.00 AKR1B1 (0.69) AKR1B1AKR1B10AKR1A1MAPT
SCHEMBL5925115 1.00 AKR1B1 (0.69) AKR1B1AKR1B10AKR1A1MAPT
SCHEMBL10577770 1.00 AKR1B1 (0.69) AKR1B1AKR1B10AKR1A1MAPT
SCHEMBL10575326 1.00 AKR1B1 (0.69) AKR1B1AKR1B10AKR1A1MAPT
SCHEMBL29392626 1.00 AKR1B1 (0.69) AKR1B1AKR1B10AKR1A1MAPT
SCHEMBL10607407 0.86 AKR1B1 (0.74) AKR1B1AKR1B10AKR1A1MAPT
SCHEMBL10575841 0.86 AKR1B1 (0.54) AKR1B1AKR1B10AKR1A1
SCHEMBL10373488 0.85 AKR1B1 (0.63) AKR1B1AKR1B10AKR1A1
SCHEMBL25892734 0.85 AKR1B1 (0.63) AKR1B1AKR1B10AKR1A1
SCHEMBL10574757 0.84 AKR1B1 (0.65) AKR1B1AKR1B10AKR1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 309 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4279580-B1 METHOD FOR SEPARATING AND CULTURING GINSENG STEM CELLS SHANGHAI KODILIN TECH CO LTD (CN) 2026-03-11 EP claimed
EP-4278892-B1 CULTURE METHOD FOR ADVENTITIOUS ROOTS OF PANAX GINSENG C. A. MEY. BY USING A BIOLOGICAL DEVICE SHANGHAI KODILIN TECH CO LTD (CN) 2026-03-11 EP claimed
CN-115389639-B Method for targeted identification of crocin compound and novel crocin compound 赣江中药创新中心 2025-04-29 CN claimed
WO-2025078426-A1 METHOD AND DEVICES FOR CULTIVATING PLANTS Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2025-04-17 WO claimed
EP-4537653-A1 METHODS AND DEVICES FOR CULTIVATING PLANTS Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2025-04-16 EP claimed
CN-118825551-A Separator, battery cell, battery and electricity utilization device 宁德时代新能源科技股份有限公司 2024-10-22 CN claimed
CN-118497242-A Novel coronavirus nucleic acid detection quality control product based on MS2 phage virus-like particles, and preparation method and application thereof 新疆生产建设兵团医院 2024-08-16 CN claimed
WO-2024053761-A1 COMPOSITION FOR PROMOTING MYOBLAST PROLIFERATION AND DIFFERENTIATION CONTAINING ALDOSE REDUCTASE INHIBITOR 애니머스큐어 주식회사 2024-03-14 WO claimed
CN-115389639-A Crocin compound targeted identification method and novel crocin compound 赣江中药创新中心 2022-11-25 CN claimed
CN-115073000-A Low-cost silver gray ceramic pigment and production method thereof 颜文静 2022-09-20 CN claimed
WO-2010065024-A1 TOPICAL TREATMENT OF CATARACTS IN DOGS KADOR PETER F (US) 2010-06-10 WO claimed
US-20090082415-A1 Topical treatment of cataracts in dogs BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA 2009-03-26 US claimed
CN-122095690-A Channel state information reporting in low power wake-up radio wireless communications 2026-05-26 CN disclosed
EP-3738240-B1 DATA RETRANSMISSION MECHANISM IN TERRESTRIAL OR NON-TERRESTRIAL NETWORKS EXHIBITING A HIGH PROPAGATION DELAY FRAUNHOFER GES FORSCHUNG (DE) 2026-05-20 EP disclosed
US-20260102514-A1 CHOLINERGIC GENE THERAPY TO PRESERVE HEARING UNIV JOHNS HOPKINS (US) 2026-04-16 US disclosed
US-12595305-B2 TREM2 stabilizing antibodies NOVARTIS AG (CH) 2026-04-07 US disclosed
EP-0172719-B1 PROCESS FOR THE PRODUCTION AS ASYMMETRIC HYDANTOINS PFIZER INC. (US) 1988-09-21 EP disclosed
US-4716113-A Process for the production of an (S)-methyl or (S)-ethyl 4-amino-6-fluorochroman-4-carboxylate PFIZER INC. (US) 1987-12-29 US disclosed
EP-0175312-A2 Process for preparing optically active hydantoins KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1986-03-26 EP disclosed
EP-0172719-A1 Process for the production as asymmetric hydantoins PFIZER INC. (US) 1986-02-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082415-A1 Topical treatment of cataracts in dogs AKR1A1, AKR1B1, AKR1C1 AKR1B1 2/4885AKR1B10 9/4885AKR1A1 1/4885
US-20260102514-A1 CHOLINERGIC GENE THERAPY TO PRESERVE HEARING CHRNA9, CHAT, CHRNB4 AKR1B1 4269/4885AKR1B10 4388/4885AKR1A1 4462/4885
US-12595305-B2 TREM2 stabilizing antibodies FCGR2A, FCGR3B, FCGR1A AKR1B1 3383/4885AKR1B10 4013/4885AKR1A1 3116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.